Data from NantHealth´s GPS Cancer platform reveals increased opportunities for HER2 directed therapy in colorectal cancer patients
(World News Science)

NantHealth Presented These Findings at the ASCO 2020 Gastrointestinal Cancers Symposium San Francisco, CA - January 25, 2020: NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced Results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patients during a poster session at the 2020 Gastrointestinal Cancer Symposium sponsored by the American Society of Clinical Oncology (ASCO). The Symposium, held at the Moscone West Building in San Francisco, CA from January 23-25, provides evidence-based teaching methods and cutting-edge learning science to a diverse audience of leaders in oncology...